Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Esa
Evaluate
December 08, 2014
ASH – Recent biotech floaters show their worth
November 07, 2014
Positive Triferic vote not a win for Rockwell just yet
August 06, 2014
Waiting game continues with Mircera launch
September 09, 2013
Rockwell steels itself for review of iron supplement
August 28, 2013
Therapeutic focus – Big pharma takes high-level interest in anaemia pills
July 03, 2013
Proposed cuts in Medicare dialysis payments could hobble industry
February 25, 2013
Spectre of Omontys safety concerns haunt Affymax again
May 18, 2012
Medgenics hopes new trial will pump up interest
December 08, 2011
Adcom puts Affymax one step closer to market
November 28, 2011
Event - Affymax heads toward crucial peginesatide vote
April 01, 2011
EASL - Protease inhibitor choice seen driven by side effects
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics